BioSpace News Archive

- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the “Company”), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that the Company will present at the Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC. The conference will take

Results of concentration study, published in JAMA Pediatrics, support abstinence from marijuana use during pregnancy and breastfeeding

Biomerics, a leading mid-market medical device contract manufacturer, announced it is expanding its manufacturing footprint in Athens, TX.

Jadex Inc., a leading manufacturing and material science company serving the medical, industrial and consumer markets, announced the retirement of current Chief Executive Officer Chuck Villa and the appointment of Dr. David Moody to serve as Chief Executive Officer, effective March 22, 2021.

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will present at the H.C. Wainwright Global Life Sciences Conference being held on March 9-10, the 33rd Annual Roth Conference

AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection, today announced the initiation of enrollment in a Phase 2 study of ABP-450 for the preventive treatment of migraine

U.S. FDA IND acceptance and IRB approval in place for investigator-sponsored trial, expected to be initiated in the second quarter of 2021

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced that the Company will report fourth quarter and full year 2020 financial results on March 23, 2021.

INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced an amendment under its exclusive U.S. commercialization agreement with Ferring Pharmaceuticals.

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2020 ended December 31, 2020, after the market closes on Monday, March 15th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.